Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as prognostic biomarkers in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab

HIGHLIGHTS

  • who: Yue Linda Wu and collaborators from the Department of Medicine, Division of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini, Pieve Emanuele have published the article: Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab, in the Journal: Cancers 2022, 5834 of 23/Nov/2022
  • what: The aim of this study was to better understand the prognostic value of NLR and PLR in a real . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?